Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Medicine Research Profiles
Home
Profiles
Departments, Divisions and Centers
Research output
PI3K Inhibitors in Breast Cancer Therapy
Haley Ellis
,
Cynthia X. Ma
Section of Medical Oncology
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Bursky Center for Human Immunology and Immunotherapy
Research output
:
Contribution to journal
›
Review article
›
peer-review
177
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'PI3K Inhibitors in Breast Cancer Therapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Phosphoinositide 3-kinase (PI3K)
100%
Breast Cancer Treatment
100%
Phosphatidylinositol 3-kinase Inhibitor
100%
Breast Cancer
60%
Phosphatidylinositol 3-kinase Pathway
40%
AKT Inhibitor
40%
Fulvestrant
40%
Hormone Receptor-positive
40%
HER2-positive
40%
Kinase Isoform
40%
Randomized Trial
20%
Clinical Trials
20%
Triple-negative Breast Cancer
20%
Therapeutic Target
20%
PIK3CA
20%
Genetic Modification
20%
Postmenopausal Women
20%
Randomized Phase II Trial
20%
Paclitaxel
20%
Antitumor Effect
20%
High Toxicity
20%
Advanced or Metastatic
20%
Clinical Benefit
20%
Therapeutic Index
20%
Hormone Receptor-positive Breast Cancer
20%
Advanced Breast Cancer
20%
AKT Pathway
20%
Alpelisib
20%
Activated Pathways
20%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphatidylinositol 3 Kinase
100%
Breast Cancer
100%
Phosphatidylinositol 3 Kinase Inhibitor
100%
Protein Kinase B
57%
Hormone Receptor
42%
Fulvestrant
28%
Triple Negative Breast Cancer
14%
Clinical Trial
14%
Paclitaxel
14%
Phase II Trials
14%
Therapeutic Window
14%
Alpelisib
14%
Diseases
14%